about
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiClinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP programResolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approachClinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL studyThe classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments
P50
Q33433659-09046388-CB98-42F0-BBDE-4AA192B5553CQ35925639-38C0777A-9C54-4646-97B1-EF6D507C50D0Q36715896-28829678-5D07-43FD-879B-FBAEE0034995Q37618904-28280FDD-9D2C-411A-98ED-CED339919786Q40318288-1C371C6A-3145-46D1-B5B9-AF44E2D8F397Q41696221-5906D8F8-CC28-426C-93F3-41EEEC8609F7Q46693258-85C711E3-3760-4209-8ABE-65DC1F5F6BACQ47093592-531CB18E-5F96-44B8-B9BB-141A904C8995Q47130656-977F7C6C-EAC5-4386-8354-66E0108A38BCQ48297666-0ABABF08-9B93-403F-A026-A5ED0130FFF3Q53174548-3D90CBDE-87C5-49FA-A1D2-9BF98C9EA4F1Q53506683-A9140072-5218-4C13-AD5B-C25A045AB69AQ56349272-CDA86923-5DCB-460B-BE83-0C91217A28A9Q84867505-73C9D4FB-D815-4293-8397-1C332B47003BQ92224914-BE7E57C1-6C46-4663-855A-909AB40BD0B0Q92224919-A6F25936-EE21-4EB4-B988-7FACA1E67FDB
P50
description
investigador
@es
researcher
@en
name
Maurizio Bonfichi
@en
type
label
Maurizio Bonfichi
@en
prefLabel
Maurizio Bonfichi
@en
P31
P496
0000-0002-7560-7291